Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Targeting of peptide‐binding receptors on cancer cells with peptide‐drug conjugates

Targeting of peptide‐binding receptors on cancer cells with peptide‐drug conjugates Specifically addressing cell surface molecules on cancer cells facilitates targeted cancer therapies that offer the potential to selectively destroy malignant cells, while sparing healthy tissue. Thus, undesired side‐effects in tumor patients are highly reduced. Peptide‐binding receptors are frequently overexpressed on cancer cells and therefore promising targets for selective tumor therapy. In this review, peptide‐binding receptors for anti‐cancer drug delivery are summarized with a focus on peptide ligands as delivery agents. In the first part, some of the most studied peptide‐binding receptors are presented, and the ghrelin receptor and the Y1 receptor are introduced as more recent targets for cancer therapy. Furthermore, nonpeptidic small molecules for receptor targeting on cancer cells are outlined. In the second part, peptide conjugates for the delivery of therapeutic cargos in cancer therapy are described. The essential properties of receptor‐targeting peptides are specified, and recent developments in the fields of classical peptide‐drug conjugates with toxic agents, radiolabeled peptides for radionuclide therapy, and boronated peptides for boron neutron capture therapy are presented. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Peptide Science Wiley

Targeting of peptide‐binding receptors on cancer cells with peptide‐drug conjugates

Loading next page...
 
/lp/wiley/targeting-of-peptide-binding-receptors-on-cancer-cells-with-peptide-GSeSqCDBbG

References (266)

Publisher
Wiley
Copyright
© 2020 Wiley Periodicals, Inc.
eISSN
2475-8817
DOI
10.1002/pep2.24171
Publisher site
See Article on Publisher Site

Abstract

Specifically addressing cell surface molecules on cancer cells facilitates targeted cancer therapies that offer the potential to selectively destroy malignant cells, while sparing healthy tissue. Thus, undesired side‐effects in tumor patients are highly reduced. Peptide‐binding receptors are frequently overexpressed on cancer cells and therefore promising targets for selective tumor therapy. In this review, peptide‐binding receptors for anti‐cancer drug delivery are summarized with a focus on peptide ligands as delivery agents. In the first part, some of the most studied peptide‐binding receptors are presented, and the ghrelin receptor and the Y1 receptor are introduced as more recent targets for cancer therapy. Furthermore, nonpeptidic small molecules for receptor targeting on cancer cells are outlined. In the second part, peptide conjugates for the delivery of therapeutic cargos in cancer therapy are described. The essential properties of receptor‐targeting peptides are specified, and recent developments in the fields of classical peptide‐drug conjugates with toxic agents, radiolabeled peptides for radionuclide therapy, and boronated peptides for boron neutron capture therapy are presented.

Journal

Peptide ScienceWiley

Published: May 1, 2020

Keywords: ; ; ; ;

There are no references for this article.